BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jodele S, Zhang K, Zou F, Laskin B, Dandoy CE, Myers KC, Lane A, Meller J, Medvedovic M, Chen J, Davies SM. The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood 2016;127:989-96. [PMID: 26603840 DOI: 10.1182/blood-2015-08-663435] [Cited by in Crossref: 95] [Cited by in F6Publishing: 101] [Article Influence: 13.6] [Reference Citation Analysis]
Number Citing Articles
1 Petr V, Csuka D, Hruba P, Szilágyi Á, Kollar M, Slavcev A, Prohászka Z, Viklicky O. MCPggaac haplotype is associated with poor graft survival in kidney transplant recipients with de novo thrombotic microangiopathy. Front Immunol 2022;13:985766. [DOI: 10.3389/fimmu.2022.985766] [Reference Citation Analysis]
2 Chan WYK, Ma ALT, Chan EYH, Kan ANC, Ng WF, Lee PPW, Cheuk DKL, Chiang AKS, Leung W, Chan GCF. Epidemiology and outcomes of pediatric transplant-associated thrombotic microangiopathy in Hong Kong. Pediatr Transplant 2022;:e14366. [PMID: 35860972 DOI: 10.1111/petr.14366] [Reference Citation Analysis]
3 Qi J, Pan T, You T, Tang Y, Chu T, Chen J, Fan Y, Hu S, Yang F, Ruan C, Wu D, Han Y. Upregulation of HIF-1α contributes to complement activation in transplantation-associated thrombotic microangiopathy. Br J Haematol 2022. [PMID: 35864790 DOI: 10.1111/bjh.18377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Ardissino G, Capone V, Tedeschi S, Porcaro L, Cugno M. Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy. Pharmaceuticals (Basel) 2022;15:845. [PMID: 35890144 DOI: 10.3390/ph15070845] [Reference Citation Analysis]
5 Meri S, Bunjes D, Cofiell R, Jodele S. The Role of Complement in HSCT-TMA: Basic Science to Clinical Practice. Adv Ther 2022. [PMID: 35781192 DOI: 10.1007/s12325-022-02184-4] [Reference Citation Analysis]
6 Elhadad S, Chadburn A, Magro C, Van Besien K, Roberson EDO, Atkinson JP, Terry H, Greenberg J, Reid W, Chapin J, Copertino D, Geramfard S, Rodriguez LB, Orfali N, Gerghis U, Shore T, Mayer S, Ahamed J, Laurence J. C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy. Bone Marrow Transplant. [DOI: 10.1038/s41409-022-01723-5] [Reference Citation Analysis]
7 Kawano N, Abe T, Ikeda N, Nagahiro Y, Kawano S, Tochigi T, Nakaike T, Yamashita K, Kubo K, Yamanaka A, Terasaka S, Marutsuka K, Mashiba K, Kikuchi I, Shimoda K, Matsumoto M, Ochiai H. Clinical features and outcomes of four atypical hemolytic uremic syndrome cases at a single institution in Miyazaki Prefecture from 2015 to 2019. Ren Replace Ther 2022;8. [DOI: 10.1186/s41100-022-00396-6] [Reference Citation Analysis]
8 Wu Y, Zuber J, Fu J. Editorial: Immunogenomics of Solid Organ and Hematopoietic Stem Cell Transplantation. Front Immunol 2022;13:878314. [PMID: 35371062 DOI: 10.3389/fimmu.2022.878314] [Reference Citation Analysis]
9 Leimi L, Jahnukainen K, Olkinuora H, Meri S, Vettenranta K. Early vascular toxicity after pediatric allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2022. [PMID: 35177827 DOI: 10.1038/s41409-022-01607-8] [Reference Citation Analysis]
10 Yang L, Zhao P, Wu Y, Fu H, He Y, Mo X, Lv M, Wang F, Yan C, Chen Y, Chang Y, Xu L, Liu K, Huang X, Zhang X. Treatment outcome and efficacy of therapeutic plasma exchange for transplant-associated thrombotic microangiopathy in a large real-world cohort study. Bone Marrow Transplant. [DOI: 10.1038/s41409-022-01581-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Rodrigues EM, Ardissino G, Pintarelli G, Capone V, Mariotti J, Verna M, Bernardo ME, Faraci M, Tozzi M, Bucalossi A, Schiavello E, Biassoni V, Guidetti A, Carotti A, Facchini L, Terruzzi E, Giglio F, Zecca M, Onida F, Caroti L, Cesaro S, Consonni D, Cugno M, Porcaro L. Gene Abnormalities in Transplant Associated-Thrombotic Microangiopathy: Comparison between Recipient and Donor's DNA. Thromb Haemost 2021. [PMID: 34965590 DOI: 10.1055/s-0041-1740498] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Gavriilaki E, Ho VT, Schwaeble W, Dudler T, Daha M, Fujita T, Jodele S. Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy. Exp Hematol Oncol 2021;10:57. [PMID: 34924021 DOI: 10.1186/s40164-021-00249-8] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Gomez-Ganda L, Benitez-Carabante MI, Fernandez-Polo A, Muñoz-Lopez M, Renedo-Miro B, Ariceta G, Diaz De Heredia C. Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy. Front Pediatr 2021;9:761726. [PMID: 34858907 DOI: 10.3389/fped.2021.761726] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Schoettler M, Chonat S, Williams K, Lehmann L. Emerging therapeutic and preventive approaches to transplant-associated thrombotic microangiopathy. Curr Opin Hematol 2021;28:408-16. [PMID: 34534983 DOI: 10.1097/MOH.0000000000000687] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Petr V, Hruba P, Kollar M, Krejci K, Safranek R, Stepankova S, Dedochova J, Machova J, Zieg J, Slatinska J, Pokorna E, Viklicky O. Rejection-associated Phenotype of De Novo Thrombotic Microangiopathy Represents a Risk for Premature Graft Loss. Transplant Direct 2021;7:e779. [PMID: 34712779 DOI: 10.1097/TXD.0000000000001239] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Gavriilaki E, Sakellari I, Chatzikonstantinou T, Bousiou Z, Mallouri D, Masmanidou M, Vardi A, Koravou EE, Kika F, Touloumenidou T, Papalexandri A, Yannaki E, Batsis I, Anagnostopoulos A. Predictors of Transplant-Associated Thrombotic Microangiopathy in Patients With Overlap or Chronic Graft-vs-Host-Disease. Transplant Proc 2021;53:2261-6. [PMID: 34417030 DOI: 10.1016/j.transproceed.2021.07.043] [Reference Citation Analysis]
17 Tamburro RF, Cooke KR, Davies SM, Goldfarb S, Hagood JS, Srinivasan A, Steiner ME, Stokes D, DiFronzo N, El-Kassar N, Shelburne N, Natarajan A; Pulmonary Complications of Pediatric Hematopoietic Stem Cell Transplantation Workshop Participants. Pulmonary Complications of Pediatric Hematopoietic Cell Transplantation. A National Institutes of Health Workshop Summary. Ann Am Thorac Soc 2021;18:381-94. [PMID: 33058742 DOI: 10.1513/AnnalsATS.202001-006OT] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
18 Yang LP, Liu X, Zhang XH. [Advances in the diagnosis and management of transplant-associated thrombotic microangiopathy]. Zhonghua Xue Ye Xue Za Zhi 2021;42:693-9. [PMID: 34547882 DOI: 10.3760/cma.j.issn.0253-2727.2021.08.018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Jodele S, Sabulski A. Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients. Expert Rev Hematol 2021;14:751-63. [PMID: 34301169 DOI: 10.1080/17474086.2021.1960816] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
20 Thomas MR, Scully M. How I treat microangiopathic hemolytic anemia in patients with cancer. Blood 2021;137:1310-7. [PMID: 33512445 DOI: 10.1182/blood.2019003810] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
21 Okamura H, Nakamae H, Shindo T, Ohtani K, Hidaka Y, Ohtsuka Y, Makuuchi Y, Kuno M, Takakuwa T, Harada N, Nishimoto M, Nakashima Y, Koh H, Hirose A, Nakamae M, Wakamiya N, Hino M, Inoue N. Early Elevation of Complement Factor Ba Is a Predictive Biomarker for Transplant-Associated Thrombotic Microangiopathy. Front Immunol 2021;12:695037. [PMID: 34326846 DOI: 10.3389/fimmu.2021.695037] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
22 Timmermans SAMEG, van Paassen P. The Syndromes of Thrombotic Microangiopathy: A Critical Appraisal on Complement Dysregulation. J Clin Med 2021;10:3034. [PMID: 34300201 DOI: 10.3390/jcm10143034] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
23 Higham CS, Collins G, Shimano KA, Melton A, Kharbanda S, Winestone LE, Huang JN, Dara J, Long-Boyle JR, Dvorak CC. Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis. Blood Adv 2021;5:2106-14. [PMID: 33877298 DOI: 10.1182/bloodadvances.2020003988] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
24 Jodele S, Medvedovic M, Luebbering N, Chen J, Dandoy CE, Laskin BL, Davies SM. Interferon-complement loop in transplant-associated thrombotic microangiopathy. Blood Adv 2020;4:1166-77. [PMID: 32208488 DOI: 10.1182/bloodadvances.2020001515] [Cited by in Crossref: 16] [Cited by in F6Publishing: 28] [Article Influence: 16.0] [Reference Citation Analysis]
25 Elfeky R, Lucchini G, Lum SH, Ottaviano G, Builes N, Nademi Z, Battersby A, Flood T, Owens S, Cant AJ, Young H, Greener S, Walsh P, Kavanagh D, Annavarapu S, Rao K, Amrolia P, Chiesa R, Worth A, Booth C, Skinner R, Doncheva B, Standing J, Gennery AR, Qasim W, Slatter M, Veys P. New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT. Blood Adv 2020;4:2418-29. [PMID: 32492158 DOI: 10.1182/bloodadvances.2019001315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
26 Fakhouri F, Frémeaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol 2021;17:543-53. [PMID: 33953366 DOI: 10.1038/s41581-021-00424-4] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
27 Luebbering N, Abdullah S, Lounder D, Lane A, Dole N, Rubinstein J, Hewison M, Gloude N, Jodele S, Perentesis KMR, Lake K, Litts B, Duell A, Dandoy CE, Davies SM. Endothelial injury, F-actin and vitamin-D binding protein after hematopoietic stem cell transplant and association with clinical outcomes. Haematologica 2021;106:1321-9. [PMID: 32241849 DOI: 10.3324/haematol.2019.233478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Valério P, Barreto JP, Ferreira H, Chuva T, Paiva A, Costa JM. Thrombotic microangiopathy in oncology - a review. Transl Oncol 2021;14:101081. [PMID: 33862523 DOI: 10.1016/j.tranon.2021.101081] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
29 Palma LMP, Sridharan M, Sethi S. Complement in Secondary Thrombotic Microangiopathy. Kidney Int Rep 2021;6:11-23. [PMID: 33102952 DOI: 10.1016/j.ekir.2020.10.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
30 Bazzan M, Todros T, Tedeschi S, Ardissino G, Cardaropoli S, Stella S, Montaruli B, Marchese C, Roccatello D, Cugno M. Genetic and molecular evidence for complement dysregulation in patients with HELLP syndrome. Thromb Res 2020;196:167-74. [PMID: 32890900 DOI: 10.1016/j.thromres.2020.08.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
31 Pagliuca S, Michonneau D, Sicre de Fontbrune F, Sutra Del Galy A, Xhaard A, Robin M, Peffault de Latour R, Socie G. Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions. Blood Adv 2019;3:2424-35. [PMID: 31409584 DOI: 10.1182/bloodadvances.2019000143] [Cited by in Crossref: 23] [Cited by in F6Publishing: 37] [Article Influence: 11.5] [Reference Citation Analysis]
32 Jodele S, Köhl J. Tackling COVID-19 infection through complement-targeted immunotherapy. Br J Pharmacol 2021;178:2832-48. [PMID: 32643798 DOI: 10.1111/bph.15187] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
33 Gavriilaki E, Sakellari I, Gavriilaki M, Anagnostopoulos A. A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity. Int J Mol Sci 2020;21:E3886. [PMID: 32485958 DOI: 10.3390/ijms21113886] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
34 Arnold SD, Brazauskas R, He N, Li Y, Hall M, Atsuta Y, Dalal J, Hahn T, Khera N, Bonfim C, Hashmi S, Parsons S, Wood WA, Steinberg A, Freytes CO, Dandoy CE, Marks DI, Lazarus HM, Abdel-Azim H, Bitan M, Diaz MA, Olsson RF, Gergis U, Seber A, Wirk B, LeMaistre CF, Ustun C, Duncan C, Rizzieri D, Szwajcer D, Fagioli F, Frangoul H, Knight JM, Kamble RT, Mehta P, Schears R, Satwani P, Pulsipher MA, Aplenc R, Saber W. The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis. Biol Blood Marrow Transplant 2020;26:1747-56. [PMID: 32464284 DOI: 10.1016/j.bbmt.2020.05.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
35 Gloude NJ, Dandoy CE, Davies SM, Myers KC, Jordan MB, Marsh RA, Kumar A, Bleesing J, Teusink-Cross A, Jodele S. Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy. J Clin Immunol 2020;40:699-707. [PMID: 32447592 DOI: 10.1007/s10875-020-00789-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
36 Wanchoo R, Stotter BR, Bayer RL, Jhaveri KD. Acute kidney injury in hematopoietic stem cell transplantation. Curr Opin Crit Care 2019;25:531-8. [PMID: 31524721 DOI: 10.1097/MCC.0000000000000657] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
37 Scordo M, Giralt S. Compliments to complement blockade for TA-TMA. Blood 2020;135:981-3. [PMID: 32219351 DOI: 10.1182/blood.2020005040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Scordo M, Giralt SA. A key step towards setting a benchmark for tackling transplant‐associated thrombotic microangiopathy. Br J Haematol 2020;189:1006-9. [DOI: 10.1111/bjh.16507] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Dandoy CE, Kim S, Chen M, Ahn KW, Ardura MI, Brown V, Chhabra S, Diaz MA, Dvorak C, Farhadfar N, Flagg A, Ganguly S, Hale GA, Hashmi SK, Hematti P, Martino R, Nishihori T, Nusrat R, Olsson RF, Rotz SJ, Sung AD, Perales MA, Lindemans CA, Komanduri KV, Riches ML. Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. JAMA Netw Open. 2020;3:e1918668. [PMID: 31913492 DOI: 10.1001/jamanetworkopen.2019.18668] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
40 Lee H, Kang E, Kang HG, Kim YH, Kim JS, Kim HJ, Moon KC, Ban TH, Oh SW, Jo SK, Cho H, Choi BS, Hong J, Cheong HI, Oh D. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020;35:25-40. [PMID: 31935318 DOI: 10.3904/kjim.2019.388] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
41 Sartain S, Shubert S, Wu M, Wang T, Martinez C. The alternative complement pathway activation product Ba as a marker for transplant‐associated thrombotic microangiopathy. Pediatr Blood Cancer 2019;67. [DOI: 10.1002/pbc.28070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
42 Patriquin CJ, Kuo KHM. Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics. Transfus Med Rev 2019;33:256-65. [PMID: 31703946 DOI: 10.1016/j.tmrv.2019.09.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
43 Tolbert VP, Dvorak CC, Golden C, Vissa M, El-haj N, Perwad F, Matthay KK, Vo KT. Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma. Biology of Blood and Marrow Transplantation 2019;25:2031-9. [DOI: 10.1016/j.bbmt.2019.06.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
44 Portuguese AJ, Gleber C, Passero FC, Lipe B. A review of thrombotic microangiopathies in multiple myeloma. Leukemia Research 2019;85:106195. [DOI: 10.1016/j.leukres.2019.106195] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
45 Bommer M, Wölfle-Guter M, Bohl S, Kuchenbauer F. The Differential Diagnosis and Treatment of Thrombotic Microangiopathies. Dtsch Arztebl Int 2018;115:327-34. [PMID: 29875054 DOI: 10.3238/arztebl.2018.0327] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
46 Luft T, Benner A, Terzer T, Jodele S, Dandoy CE, Storb R, Kordelas L, Beelen D, Gooley T, Sandmaier BM, Sorror M, Zeisbrich M, Radujkovic A, Dreger P, Penack O. EASIX and mortality after allogeneic stem cell transplantation. Bone Marrow Transplant 2020;55:553-61. [PMID: 31558788 DOI: 10.1038/s41409-019-0703-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
47 Pan T, Qi J, You T, Han S, Yang L, Miao W, Wu D, Ruan C, Zhu L, Han Y. Circulating Heme Oxygenase-1 and Complement Activation in Transplant-Associated Thrombotic Microangiopathy. Biology of Blood and Marrow Transplantation 2019;25:1486-91. [DOI: 10.1016/j.bbmt.2019.03.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
48 Ma Q, Li D, Vasquez HG, You MJ, Afshar-Kharghan V. Kidney Injury in Murine Models of Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2019;25:1920-4. [PMID: 31271886 DOI: 10.1016/j.bbmt.2019.06.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
49 Schönermarck U, Ries W, Schröppel B, Pape L, Dunaj-Kazmierowska M, Burst V, Mitzner S, Basara N, Starck M, Schmidbauer D, Mellmann A, Dittmer R, Jeglitsch M, Haas CS. Relative incidence of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in clinically suspected cases of thrombotic microangiopathy. Clin Kidney J 2020;13:208-16. [PMID: 32296526 DOI: 10.1093/ckj/sfz066] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
50 Le Clech A, Simon-tillaux N, Provôt F, Delmas Y, Vieira-martins P, Limou S, Halimi J, Le Quintrec M, Lebourg L, Grangé S, Karras A, Ribes D, Jourde-chiche N, Rondeau E, Frémeaux-bacchi V, Fakhouri F. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. Kidney International 2019;95:1443-52. [DOI: 10.1016/j.kint.2019.01.023] [Cited by in Crossref: 31] [Cited by in F6Publishing: 42] [Article Influence: 10.3] [Reference Citation Analysis]
51 Gavriilaki E, Gkaliagkousi E, Grigoriadis S, Anyfanti P, Douma S, Anagnostopoulos A. Hypertension in hematologic malignancies and hematopoietic cell transplantation: An emerging issue with the introduction of novel treatments. Blood Reviews 2019;35:51-8. [DOI: 10.1016/j.blre.2019.03.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
52 Dvorak CC, Higham C, Shimano KA. Transplant-Associated Thrombotic Microangiopathy in Pediatric Hematopoietic Cell Transplant Recipients: A Practical Approach to Diagnosis and Management. Front Pediatr 2019;7:133. [PMID: 31024873 DOI: 10.3389/fped.2019.00133] [Cited by in Crossref: 26] [Cited by in F6Publishing: 38] [Article Influence: 8.7] [Reference Citation Analysis]
53 Park MH, Caselman N, Ulmer S, Weitz IC. Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv 2018;2:2090-4. [PMID: 30131343 DOI: 10.1182/bloodadvances.2018019596] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
54 Galbusera M, Noris M, Gastoldi S, Bresin E, Mele C, Breno M, Cuccarolo P, Alberti M, Valoti E, Piras R, Donadelli R, Vivarelli M, Murer L, Pecoraro C, Ferrari E, Perna A, Benigni A, Portalupi V, Remuzzi G. An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. Am J Kidney Dis 2019;74:56-72. [PMID: 30851964 DOI: 10.1053/j.ajkd.2018.11.012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 8.7] [Reference Citation Analysis]
55 Schoettler M, Lehmann L, Li A, Ma C, Duncan C. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors. Biol Blood Marrow Transplant 2019;25:e163-8. [PMID: 30639820 DOI: 10.1016/j.bbmt.2018.12.840] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
56 Merrill SA, Brodsky RA. Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria. Hematology Am Soc Hematol Educ Program 2018;2018:371-6. [PMID: 30504334 DOI: 10.1182/asheducation-2018.1.371] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
57 Sartain S, Shubert S, Wu M, Srivaths P, Teruya J, Krance R, Martinez C. Therapeutic Plasma Exchange does not Improve Renal Function in Hematopoietic Stem Cell Transplantation–Associated Thrombotic Microangiopathy: An Institutional Experience. Biology of Blood and Marrow Transplantation 2019;25:157-62. [DOI: 10.1016/j.bbmt.2018.08.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
58 Schuh MP, Bennett MR, Lane A, Jodele S, Laskin BL, Devarajan P. Haptoglobin degradation product as a novel serum biomarker for hematopoietic stem cell transplant-associated thrombotic microangiopathy. Pediatr Nephrol 2019;34:865-71. [PMID: 30569313 DOI: 10.1007/s00467-018-4178-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
59 Postalcioglu M, Kim HT, Obut F, Yilmam OA, Yang J, Byun BC, Kupiec-weglinski S, Soiffer R, Ritz J, Antin JH, Alyea E, Koreth J, Cutler C, Armand P, Paik JM, Leaf DE, Ho VT, Abdi R. Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2018;24:2344-53. [DOI: 10.1016/j.bbmt.2018.05.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
60 Ardissino G, Cresseri D, Giglio F, Onida F, Iannuzzella F, Tel F, Giussani A, Messa P, Longhi S, Vincenti D, Tedeschi S, Cugno M, Ciceri F. Haploidentical Hematopoietic Stem Cell Transplant Complicated by Atypical Hemolytic Uremic Syndrome and Kidney Transplant From the Same Donor With No Immunosuppression but C5 Inhibition. Transplantation 2019;103:e48-51. [PMID: 30365467 DOI: 10.1097/TP.0000000000002505] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
61 Genere L, Bacchetta J, Bertrand Y, Javouhey E, Cheikh N, Sellier-Leclerc AL. Eculizumab and thrombotic microangiopathy after hematopoietic stem cell transplantation: A report on its efficacy and safety in two pediatric patients. Arch Pediatr 2018;25:485-8. [PMID: 30340942 DOI: 10.1016/j.arcped.2018.09.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
62 Gavriilaki E, Sakellari I, Batsis I, Mallouri D, Bousiou Z, Vardi A, Yannaki E, Constantinou V, Tsompanakou A, Vadikoliou C, Kaloyannidis P, Bamihas G, Anagnostopoulos A. Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation. Clin Transplant 2018;32:e13371. [DOI: 10.1111/ctr.13371] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
63 Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D. Developments in anti-complement therapy; from disease to clinical trial. Mol Immunol 2018;102:89-119. [PMID: 30121124 DOI: 10.1016/j.molimm.2018.06.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 10.3] [Reference Citation Analysis]
64 Romick-Rosendale LE, Haslam DB, Lane A, Denson L, Lake K, Wilkey A, Watanabe M, Bauer S, Litts B, Luebbering N, Dandoy CE, Davies SM. Antibiotic Exposure and Reduced Short Chain Fatty Acid Production after Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant 2018;24:2418-24. [PMID: 30055351 DOI: 10.1016/j.bbmt.2018.07.030] [Cited by in Crossref: 35] [Cited by in F6Publishing: 50] [Article Influence: 8.8] [Reference Citation Analysis]
65 Kato H, Miyakawa Y, Hidaka Y, Inoue N, Ito S, Kagami S, Kaname S, Matsumoto M, Mizuno M, Matsuda T, Shimono A, Maruyama S, Fujimura Y, Nangaku M, Okada H. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clin Exp Nephrol 2019;23:65-75. [PMID: 29959568 DOI: 10.1007/s10157-018-1609-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
66 Wirtschafter E, VanBeek C, Linhares Y. Bone marrow transplant-associated thrombotic microangiopathy without peripheral blood schistocytes: a case report and review of the literature. Exp Hematol Oncol. 2018;7:14. [PMID: 29977661 DOI: 10.1186/s40164-018-0106-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
67 Risitano AM. Therapeutic complement modulation for hematological diseases: Where we stand and where we are going. Semin Hematol 2018;55:113-7. [PMID: 30032746 DOI: 10.1053/j.seminhematol.2018.05.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
68 Jodele S. Complement in Pathophysiology and Treatment of Transplant-Associated Thrombotic Microangiopathies. Semin Hematol 2018;55:159-66. [PMID: 30032753 DOI: 10.1053/j.seminhematol.2018.04.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
69 Sartain SE, Turner NA, Moake JL. Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells. J Biol Chem 2018;293:7195-208. [PMID: 29555686 DOI: 10.1074/jbc.RA118.002639] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
70 Tie R, Zhang T, Yang B, Fu H, Han B, Yu J, Tan Y, Huang H. Clinical implications of HLA locus mismatching in unrelated donor hematopoietic cell transplantation: a meta-analysis. Oncotarget 2017;8:27645-60. [PMID: 28206973 DOI: 10.18632/oncotarget.15291] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
71 Buchbinder D, Kelly DL, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick AB, Wirk BM, Yi J, Battiwalla M, Flowers MDE, Savani B, Shaw BE. Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplant 2018;53:535-55. [PMID: 29343837 DOI: 10.1038/s41409-017-0055-7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 9.3] [Reference Citation Analysis]
72 Weitz IC. Thrombotic microangiopathy in cancer. Thromb Res 2018;164 Suppl 1:S103-5. [PMID: 29703465 DOI: 10.1016/j.thromres.2018.01.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
73 Gavriilaki E, Sakellari I, Mallouri D, Batsis I, Yannaki E, Anagnostopoulos A. Unraveling the Genetics of Transplant-Associated Thrombotic Microangiopathy: Lessons to be Learned. Biology of Blood and Marrow Transplantation 2017;23:2013-4. [DOI: 10.1016/j.bbmt.2017.07.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
74 Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018;13:300-317. [PMID: 29042465 DOI: 10.2215/cjn.00620117] [Cited by in Crossref: 103] [Cited by in F6Publishing: 112] [Article Influence: 20.6] [Reference Citation Analysis]
75 Upperman JS, Lacroix J, Curley MA, Checchia PA, Lee DW, Cooke KR, Tamburro RF. Specific Etiologies Associated With the Multiple Organ Dysfunction Syndrome in Children: Part 1. Pediatr Crit Care Med 2017;18:S50-7. [PMID: 28248834 DOI: 10.1097/PCC.0000000000001048] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
76 Seaby EG, Gilbert RD. Thrombotic microangiopathy following haematopoietic stem cell transplant. Pediatr Nephrol 2018;33:1489-500. [PMID: 28993886 DOI: 10.1007/s00467-017-3803-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
77 Laskin BL, Jodele S. Kidney Disease in Cancer Survivors: Focus on Hematopoietic Stem Cell Transplantation. Journal of Onco-Nephrology 2017;1:163-9. [DOI: 10.5301/jo-n.5000031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
78 Kelly DL, Buchbinder D, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick A, Wirk BM, Yi J, Battiwalla M, Flowers ME, Savani B, Shaw BE. Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2018;24:228-41. [PMID: 28939455 DOI: 10.1016/j.bbmt.2017.09.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
79 Bohl SR, Kuchenbauer F, von Harsdorf S, Kloevekorn N, Schönsteiner SS, Rouhi A, Schwarzwälder P, Döhner H, Bunjes D, Bommer M. Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy. Biol Blood Marrow Transplant 2017;23:2172-7. [PMID: 28860002 DOI: 10.1016/j.bbmt.2017.08.019] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 6.4] [Reference Citation Analysis]
80 Ardissino G, Tedeschi S, Zecca M, Berra S, Colussi G, Giglio F, Terruzzi E, Cugno M. Response. Biol Blood Marrow Transplant 2017;23:2014-5. [PMID: 28821453 DOI: 10.1016/j.bbmt.2017.07.017] [Reference Citation Analysis]
81 Qi J, Wang J, Chen J, Su J, Tang Y, Wu X, Ma X, Chen F, Ruan C, Zheng XL, Wu D, Han Y. Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation. Ann Hematol 2017;96:1849-55. [PMID: 28801815 DOI: 10.1007/s00277-017-3092-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
82 Goodship THJ, Pinto F, Weston-Davies WH, Silva J, Nishimura JI, Nunn MA, Mackie I, Machin SJ, Palm L, Pryce JW, Chiesa R, Amrolia P, Veys P. Use of the complement inhibitor Coversin to treat HSCT-associated TMA. Blood Adv 2017;1:1254-8. [PMID: 29296765 DOI: 10.1182/bloodadvances.2016002832] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
83 Ardissino G, Salardi S, Berra S, Colussi G, Cugno M, Zecca M, Giglio F, Peccatori J, Diral E, Tel F, Clivio A, Tedeschi S. Acquired Complement Regulatory Gene Mutations and Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy. Biol Blood Marrow Transplant 2017;23:1580-2. [PMID: 28522344 DOI: 10.1016/j.bbmt.2017.05.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
84 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
85 Jodele S. Double trouble: Complement-mediated thrombotic microangiopathy in patients with hemoglobinopathies after stem cell transplantation. Pediatr Blood Cancer 2017;64. [PMID: 28449196 DOI: 10.1002/pbc.26566] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
86 Masias C, Vasu S, Cataland SR. None of the above: thrombotic microangiopathy beyond TTP and HUS. Blood 2017;129:2857-63. [PMID: 28416509 DOI: 10.1182/blood-2016-11-743104] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
87 Abusin GA, Abu-Arja R, Bajwa RPS, Horwitz EM, Auletta JJ, Rangarajan HG. Severe transplant-associated thrombotic microangiopathy in patients with hemoglobinopathies. Pediatr Blood Cancer 2017;64. [PMID: 28333416 DOI: 10.1002/pbc.26503] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
88 Gavriilaki E, Sakellari I, Anagnostopoulos A, Brodsky RA. Transplant-associated thrombotic microangiopathy: opening Pandora's box. Bone Marrow Transplant 2017;52:1355-60. [PMID: 28287636 DOI: 10.1038/bmt.2017.39] [Cited by in Crossref: 36] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
89 Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet 2017;390:681-96. [PMID: 28242109 DOI: 10.1016/S0140-6736(17)30062-4] [Cited by in Crossref: 202] [Cited by in F6Publishing: 216] [Article Influence: 40.4] [Reference Citation Analysis]
90 Sahin U, Ataca Atilla P, Atilla E, Toprak SK, Demirer T. An overview of hematopoietic stem cell transplantation related thrombotic complications. Critical Reviews in Oncology/Hematology 2016;107:149-55. [DOI: 10.1016/j.critrevonc.2016.09.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
91 Dhakal P, Bhatt VR. Is complement blockade an acceptable therapeutic strategy for hematopoietic cell transplant-associated thrombotic microangiopathy? Bone Marrow Transplant 2017;52:352-6. [PMID: 27775697 DOI: 10.1038/bmt.2016.253] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
92 Shen YM. Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome. Thromb J 2016;14:19. [PMID: 27766045 DOI: 10.1186/s12959-016-0114-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
93 Sakellari I, Gavriilaki E, Boussiou Z, Batsis I, Mallouri D, Constantinou V, Kaloyannidis K, Yannaki E, Bamihas G, Anagnostopoulos A. Transplant-associated thrombotic microangiopathy: an unresolved complication of unrelated allogeneic transplant for hematologic diseases. Hematological Oncology 2017;35:932-4. [DOI: 10.1002/hon.2346] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
94 Kavanagh D, Smith-Jackson K. Eculizumab in children with hemolytic uremic syndrome. Kidney Int 2016;89:537-8. [PMID: 26880449 DOI: 10.1016/j.kint.2015.12.039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
95 Risitano AM, Marotta S. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future. Semin Immunol 2016;28:223-40. [PMID: 27346521 DOI: 10.1016/j.smim.2016.05.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
96 Dandoy CE, Haslam D, Lane A, Jodele S, Demmel K, El-Bietar J, Flesch L, Myers KC, Pate A, Rotz S, Daniels P, Wallace G, Nelson A, Waters H, Connelly B, Davies SM. Healthcare Burden, Risk Factors, and Outcomes of Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infections after Stem Cell Transplantation. Biol Blood Marrow Transplant 2016;22:1671-7. [PMID: 27311966 DOI: 10.1016/j.bbmt.2016.06.002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
97 Teoh CW, Riedl M, Licht C. The alternative pathway of complement and the thrombotic microangiopathies. Transfus Apher Sci. 2016;54:220-231. [PMID: 27160864 DOI: 10.1016/j.transci.2016.04.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
98 Jodele S, Dandoy CE, Myers KC, El-Bietar J, Nelson A, Wallace G, Laskin BL. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transfus Apher Sci. 2016;54:181-190. [PMID: 27156964 DOI: 10.1016/j.transci.2016.04.007] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 10.3] [Reference Citation Analysis]
99 Palma LM, Langman CB. Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. J Blood Med 2016;7:39-72. [PMID: 27110144 DOI: 10.2147/JBM.S36249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 0.3] [Reference Citation Analysis]
100 Obut F, Kasinath V, Abdi R. Post-bone marrow transplant thrombotic microangiopathy. Bone Marrow Transplant 2016;51:891-7. [DOI: 10.1038/bmt.2016.61] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
101 Pulsipher MA. Fishing for complements. Blood 2016;127:957-8. [PMID: 26917734 DOI: 10.1182/blood-2015-12-685131] [Reference Citation Analysis]